Headlines about Achillion Pharmaceuticals (NASDAQ:ACHN) have been trending somewhat positive recently, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Achillion Pharmaceuticals earned a news sentiment score of 0.24 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 47.9279538675293 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the media headlines that may have effected Accern’s rankings:
- Achillion Pharma (ACHN) Secures FDA Orphan Drug Designation and Positive Opinion for Orphan Drug Designation … – StreetInsider.com (streetinsider.com)
- What Technical Analysis say About Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)? – The Oracle Examiner (oracleexaminer.com)
- Achillion Pharma (ACHN) Secures FDA Orphan Drug Designation and Positive Opinion for Orphan Drug Designation in the European Union for ACH-4471 (streetinsider.com)
- Achillion Announces ACH-4471 Granted Orphan Drug Designation by the FDA and Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (finance.yahoo.com)
- Achillion Pharmaceuticals, Inc. (ACHN) Upgraded to “Buy” at Zacks Investment Research (americanbankingnews.com)
Shares of Achillion Pharmaceuticals (NASDAQ ACHN) opened at $3.89 on Friday. Achillion Pharmaceuticals has a 12 month low of $3.15 and a 12 month high of $5.66.
Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.04. During the same quarter in the prior year, the business earned ($0.15) earnings per share. research analysts expect that Achillion Pharmaceuticals will post -0.63 earnings per share for the current fiscal year.
A number of equities research analysts have weighed in on ACHN shares. BidaskClub lowered shares of Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, July 25th. Zacks Investment Research raised shares of Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, September 14th. Ladenburg Thalmann Financial Services reduced their target price on shares of Achillion Pharmaceuticals from $9.00 to $6.50 and set a “buy” rating on the stock in a report on Tuesday, September 12th. Maxim Group set a $7.00 target price on shares of Achillion Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 9th. Finally, Chardan Capital reissued a “neutral” rating on shares of Achillion Pharmaceuticals in a report on Sunday, September 17th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $5.33.
COPYRIGHT VIOLATION NOTICE: This story was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://stocknewstimes.com/2017/11/12/achillion-pharmaceuticals-achn-given-daily-media-sentiment-score-of-0-24.html.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.